Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andreas Engert

Showing results (241-250 of 379) with videos related to

Pageof 38
Sort By:
Blood|July 13, 2012
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experienceAchim Rothe, Stephanie Sasse, Helen Goergen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2021
Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancerCarolin E M Jakob, Annika Y Classen, Melanie Stecher, et al.
Plos One|April 29, 2016
Evidence of Inbreeding in Hodgkin LymphomaHauke Thomsen, Miguel Inacio da Silva Filho, Michael Fuchs, et al.
Blood|July 26, 2003
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann, John F Treml, Hinrich Hansen, et al.
International Journal of Cancer|February 22, 2002
Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxinHinrich P Hansen, Bärbel Matthey, Stefan Barth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study GroupLucia Nogová, Thorsten Reineke, Corinne Brillant, et al.
The Lancet. Haematology|August 2, 2016
Costs of haematological disease high and risingTony Green, Dominique Bron, Christine Chomienne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study groupDiana Wongso, Michael Fuchs, Annette Plütschow, et al.
Springerplus|January 24, 2014
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Carsten Zwick, Marita Ziepert, et al.
Leukemia|October 10, 2021
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysisPaul J Bröckelmann, Horst Müller, Sarah Gillessen, et al.
Pageof 38

Showing results (241-250 of 379) with videos related to

Sort By:
Pageof 38
Blood|July 13, 2012
Brentuximab vedotin for relapsed or refractory CD30+ hematologic malignancies: the German Hodgkin Study Group experienceAchim Rothe, Stephanie Sasse, Helen Goergen, et al.
European Journal of Cancer (Oxford, England : 1990)|August 16, 2021
Association between the dietary regimen and infection-related complications in neutropenic high-risk patients with cancerCarolin E M Jakob, Annika Y Classen, Melanie Stecher, et al.
Plos One|April 29, 2016
Evidence of Inbreeding in Hodgkin LymphomaHauke Thomsen, Miguel Inacio da Silva Filho, Michael Fuchs, et al.
Blood|July 26, 2003
The human anti-CD30 antibody 5F11 shows in vitro and in vivo activity against malignant lymphomaPeter Borchmann, John F Treml, Hinrich Hansen, et al.
International Journal of Cancer|February 22, 2002
Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxinHinrich P Hansen, Bärbel Matthey, Stefan Barth, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 19, 2007
Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study GroupLucia Nogová, Thorsten Reineke, Corinne Brillant, et al.
The Lancet. Haematology|August 2, 2016
Costs of haematological disease high and risingTony Green, Dominique Bron, Christine Chomienne, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 26, 2013
Treatment-related mortality in patients with advanced-stage hodgkin lymphoma: an analysis of the german hodgkin study groupDiana Wongso, Michael Fuchs, Annette Plütschow, et al.
Springerplus|January 24, 2014
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHLKarin Hohloch, Carsten Zwick, Marita Ziepert, et al.
Leukemia|October 10, 2021
Clinical outcomes of relapsed and refractory Hodgkin lymphoma patients after contemporary first-line treatment: a German Hodgkin Study Group analysisPaul J Bröckelmann, Horst Müller, Sarah Gillessen, et al.
Pageof 38